Amplia Therapeutics (ASX:ATX) has announced that an additional confirmed partial response has been recorded in its ongoing ACCENT clinical trial in pancreatic cancer.
The trial is investigating Amplia's FAK inhibitor narmafotinib in combination with standard-of-care chemotherapies, gemcitabine and abraxane. The company said this additional confirmed partial response brings the objective response rate to 29 per cent, or 16 out of 55 patients enrolled in the trial. There are 20 patients still enrolled in the trial.
A confirmed partial response is a formal designation of response where tumour shrinkage over 30 per cent is recorded and sustained for two or more months and where no new cancerous lesions have been detected.
Amplia CEO and Managing Director, Dr Chris Burns: “An additional confirmed PR [partial response] adds to the promising data already recorded in the ACCENT trial. With 20 patients still on study we are hopeful that further PR’s will be recorded in the future.”